Amyris completes first major license for leading rna vaccine advancing technology to human trials

Emeryville, calif., july 1, 2021 /prnewswire/ -- amyris, inc. (nasdaq: amrs), a leading synthetic biotechnology company active in the clean health and beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it has signed an exclusive license with nant africa, llc relating to the development and use of the rna covid vaccine amyris developed in coordination with the infectious disease research institute (idri).
AMRS Ratings Summary
AMRS Quant Ranking